Editor’s Note: As we’ve previously reported, NVG-291 is an experimental drug that has shown promising results in restoring movement after spinal cord injury. The research team is now accepting volunteers for its Phase 1b/2a study in Chicago, where local news station, WGN TV, recently covered this story.
Researchers at the Shirley Ryan AbilityLab are recruiting individuals with chronic (1-10 years) and subacute (10-49 days) cervical spinal cord injury (incomplete) to test the safety and efficacy of an experimental drug, NVG-291.
NVG-291 is neuroreparative therapeutic injection that has the potential to treat nervous system damage resulting from traumatic injury or disease. Previous lab studies have shown promising results, with NVG-291 demonstrating improvements in movement and bladder recovery among individuals with spinal cord injuries.
“This is a first of its kind study for people with spinal cord injury,” said Dr. Monica Perez, the scientific chair of the Arms and Hands Lab at Shirley Ryan. “We’re trying to restore as much ability as possible in patients. We target the ability to perform movements with the arms, grasp for example, or we target the ability to walk.”
The research team hopes to enroll several participants with chronic cervical spine damage, meaning one to 10 years post-injury, and those who have minimal hand movement and the ability to take a step. Study participants receive daily injections under the skin for 12 weeks. Upper and lower limb function will be assessed after 16 weeks.
For more information, visit: The Connect SCI Study.
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Leave a Reply